MedTrace Logo

Assessment of Sublingual Immunotherapy in Children Allergic to House Dust Mites

NCT01052610 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2013-02-07

No results posted yet for this study

Summary

The purpose of the trial is to asses the efficacy and safety of sublingual annual immunotherapy in children with bronchial asthma and/or allergic rhinitis allergic to house dust mites.

Conditions

  • Bronchial Asthma
  • Allergic Rhinitis

Interventions

DRUG

sublingual house dust mites allergen extract

Staloral 300 IR, Stallergenes, France

DRUG

placebo in sublingual applicator

placebo for Staloral 300 IR, Stallergenes, France

Sponsors & Collaborators

  • Medical University of Lodz

    lead OTHER

Principal Investigators

  • Iwona Stelmach, MD, PhD, Prof · Department of Pediatrics and Allergy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2013-09-30
Completion
2013-09-30

Countries

  • Poland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01052610 on ClinicalTrials.gov